Vesalius Longevity Labs announced that it has entered a partnership with Wisp, the largest women’s telehealth provider in the U.S., to jointly create a suite of peptide therapeutics designed specifically for women. According to the company, the project aims to address longevity and health-span interventions that focus on female biology.
The co-developed products will form an exclusive line targeting fertility, hormonal balance, and menopause and will build on Vesalius’ existing Peptual™ portfolio of injectables, patches, nasal sprays, oral and topical formulations manufactured in U.S.-sourced, FDA-registered, cGMP-compliant facilities.
Vesalius and Wisp also said they will evaluate artificial intelligence-driven platforms to support personalised care, including clinical decision support, patient engagement and precision treatment matching. The first products from this collaboration are expected to launch in early 2026.
The partnership is positioned by the company as a strategic effort to expand into a fast-growing peptide therapeutics market — which it states is valued at approximately US$43.1 billion globally and projected to reach US$106 billion by 2033 — and to redirect its focus to female-specific longevity solutions.
Wisp, which serves more than 1.5 million women across the U.S., will bring its telehealth scale and women’s-health expertise to the collaboration. The companies said that combining Vesalius’ longevity science with Wisp’s women’s-health platform will create an “era” of advanced solutions for women’s ageing.
